tiprankstipranks
Wells downgrades Edwards Lifesciences with Medtronic gaining share
The Fly

Wells downgrades Edwards Lifesciences with Medtronic gaining share

Wells Fargo downgraded Edwards Lifesciences to Equal Weight (EW) from Overweight with a price target of $78, down from $97. The analyst sees limited upside to transcatheter aortic valve replacement market growth with Edwards growing below market due to increasing competition. Channel checks and third-party data show Medtronic (MDT) is gaining some share with Evolut FX while Abbott’s (ABT) recently approved Navitor is competing on price and Boston Scientific (BSX) is launching Accurate Neo2 in the U.S. in 2024, the analyst tells investors in a research note. The firms also sees no major TAVR data catalysts for Edwards Lifesciences for almost two years.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on EW:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles